In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as skin, lung, or bone and soft tissue cancer (sarcomas), they have not yet proven themselves as a treatment method. Tumor shrinkage was achieved only in rare cases, but the side effects were all the more severe. An international research group led by scientists has now succeeded in a phase 1 clinical trial in testing a novel cell therapy approach that also shows promise for solid tumors.

Iron-rich hematite, commonly found in rocks and soil, turns out to have magnetic properties that make it a promising material for ultrafast next-generation computing.

People with the hereditary disease familial adenomatous polyposis (FAP) have a greatly increased risk of developing a malignant tumor of the duodenum. Researchers have now discovered a mechanism in the local immune system that can drive the development of cancer. They see this as a promising new approach to preventing duodenal carcinoma in people with FAP.

Historically, small molecule drugs have been precisely designed down to the atomic scale. Considering their relatively large complex structures, nanomedicines have lagged behind. Researchers argue this precise control should be applied to optimize new nanomedicines.

Researchers have discovered a new biomarker for Parkinson's disease. A misfolded protein facilitates reliable diagnosis even in the early stages of Parkinson's disease in body fluids.